Dorothée Möller

Title: Dorothée Möller: Innovator in Beta-2 Selective Adrenergic Receptor Agonists

Introduction

Dorothée Möller is a notable inventor based in Erlangen, Germany. He has made significant contributions to the field of pharmacology, particularly in the development of beta-2 selective adrenergic receptor agonists. His work focuses on creating compounds that can effectively treat various bronchoconstrictive diseases while minimizing side effects.

Latest Patents

Möller holds a patent for "Beta-2 selective adrenergic receptor agonists." This patent includes conformationally restricted analogs of catecholamine-type compounds, such as isoprenaline, adrenaline, and noradrenaline. These compounds are designed to activate the β2AR with high selectivity over the β1AR. The beta-2 selective adrenergic receptor agonist compounds may serve as bronchodilators and find use in treating a variety of bronchoconstrictive diseases and conditions. The patent also outlines methods for treating preterm labor and acute asthma, providing a means to reduce undesirable side effects associated with non-selective β-adrenergic receptor agonism. Additionally, the compounds can be utilized to prevent or treat heart failure.

Career Highlights

Throughout his career, Dorothée Möller has worked with prestigious institutions, including Leland Stanford Junior University and the University of California. His research has significantly advanced the understanding and treatment of respiratory conditions.

Collaborations

Möller has collaborated with esteemed colleagues such as Roger K. Sunahara and Harald Huebner. These partnerships have contributed to the development of innovative therapeutic approaches in his field.

Conclusion

Dorothée Möller's work in the realm of beta-2 selective adrenergic receptor agonists exemplifies his commitment to improving medical treatments for respiratory conditions. His innovative approaches and collaborations continue to influence the field of pharmacology.